Evidence map›Paper›PMID 40138026›Full record

ArticleNeurogenetics2025

Mitochondrial DNA variants revealed by whole exome sequencing: from screening to diagnosis and follow-up.

Sebastian Skoczylas, Tomasz Płoszaj, Karolina Gadzalska, Monika Gorządek, Paulina Jakiel, Ewa Juścińska, Maria Malarska, Magdalena Traczyk-Borszyńska, Hanna Biezynska, Magdalena Rychlik and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sebastian SkoczylasDepartment of Clinical Genetics, Lodz, Poland. sebastian.skoczylas@umed.lodz.pl.ORCID https://orcid.org/0000-0003-2760-2397
Tomasz PłoszajDepartment of Clinical Genetics, Lodz, Poland.
Karolina GadzalskaDepartment of Clinical Genetics, Lodz, Poland.
Monika GorządekDepartment of Clinical Genetics, Lodz, Poland.
Paulina JakielDepartment of Clinical Genetics, Lodz, Poland.
Ewa JuścińskaDepartment of Clinical Genetics, Lodz, Poland.
Maria MalarskaDepartment of Clinical Genetics, Lodz, Poland.
Magdalena Traczyk-BorszyńskaDepartment of Clinical Genetics, Lodz, Poland.
Hanna BiezynskaStudent Society for Genetic Counseling and Clinical Genetics, Department of Clinical Genetics, Medical University of Lodz, Pomorska Str. 251, Lodz, 92-213, Poland.
Magdalena RychlikStudent Society for Genetic Counseling and Clinical Genetics, Department of Clinical Genetics, Medical University of Lodz, Pomorska Str. 251, Lodz, 92-213, Poland.
Agata PastorczakDepartment of Genetic Predisposition to Cancer, Medical University of Lodz, Lodz, Poland.
Agnieszka ZmysłowskaDepartment of Clinical Genetics, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in mitochondrial DNA play a crucial role in several diseases, but interpreting the clinical significance of mitochondrial DNA variants is challenging due to heteroplasmy, age-related loss of variants and evolving phenotypes. The aim of study was to identify mitochondrial pathogenic variants and explore their potential future association with specific phenotypes in patients during their lifetime, for both known and novel variants. We used a Python pipeline to analyse exome sequencing data from 418 patients (median age: 15 years; 52.9% males and 47.1% females), mostly diagnosed with neurological disorders, developmental and intellectual disabilities, behavioural and sensory disorders, cardiovascular and metabolic abnormalities, renal diseases and others. Screening identified 1,000 unique variants with heteroplasmy levels greater than 10% and 192 unique variants with 1-10% heteroplasmy, excluding hypervariable regions. Among these variants, four confirmed pathogenic variants were detected according to MITOMAP (m.1555 A > G, m.3243 A > G, m.9035T > C, and m.11778G > A), each identified in one patient. The application of pathogenicity and frequency criteria led to the identification of three unique variants and one in monozygotic twin sister with low levels of heteroplasmy, which were confirmed by next-generation sequencing. Finally, one of them, the variant m.15897G > A, was recognised as likely pathogenic (PP3, PS2). Our study highlights the complexity of diagnosing mitochondrial diseases associated with mtDNA mutations and emphasises the need for a comprehensive genotype-phenotype approach to correctly identify causal variants.

Indexed as

DNA, MitochondrialMitochondrial DiseasesAdolescentAdultChildChild, PreschoolExome SequencingFemaleFollow-Up StudiesGenetic TestingGenetic VariationHeteroplasmyHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedDNA, MitochondrialMitochondrial diseasesmtdnamtdna variantsWhole exome sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.